| Title: | Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosis |
| Journal: | Haematologica |
| Published: | 15 Jun 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37317877/ |
| DOI: | https://doi.org/10.3324/haematol.2023.282913 |
| URL: | https://haematologica.org/article/download/haematol.2023.282913/75702 |
Publication 11564
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Hereditary erythrocytosis is a rare hematologic disorder characterized by an excess of red blood cell production. Here we describe a European collaborative study involving a collection of 2,160 patients with erythrocytosis sequenced in ten different laboratories. We focused our study on the EGLN1 gene and identified 39 germline missense variants including one gene deletion in 47 probands. EGLN1 encodes the PHD2 prolyl 4-hydroxylase, a major inhibitor of hypoxia-inducible factor. We performed a comprehensive study to evaluate the causal role of the identified PHD2 variants: (i) in silico studies of localization, conservation, and deleterious effects; (ii) analysis of hematologic parameters of carriers identified in the UK Biobank; (iii) functional studies of the protein activity and stability; and (iv) a comprehensive study of PHD2 splicing. Altogether, these studies allowed the classification of 16 pathogenic or likely pathogenic mutants in a total of 48 patients and relatives. The in silico studies extended to the variants described in the literature showed that a minority of PHD2 variants can be classified as pathogenic (36/96), without any differences from the variants of unknown significance regarding the severity of the developed disease (hematologic parameters and complications). Here, we demonstrated the great value of federating laboratories working on such rare disorders in order to implement the criteria required for genetic classification, a strategy that should be extended to all hereditary hematologic diseases.</p>
42 Authors
- Marine Delamare
- Amandine Le Roy
- Mathilde Pacault
- Loïc Schmitt
- Céline Garrec
- Nada Maaziz
- Matti Myllykoski
- Antoine Rimbert
- Valéna Karaghiannis
- Bernard Aral
- Mark Catherwood
- Fabrice Airaud
- Lamisse Mansour-Hendili
- David Hoogewijs
- Edoardo Peroni
- Salam Idriss
- Valentine Lesieur
- Amandine Caillaud
- Karim Si-Tayeb
- Caroline Chariau
- Anne Gaignerie
- Minke Rab
- Torsten Haferlach
- Manja Meggendorfer
- Stéphane Bézieau
- Andrea Benetti
- Nicole Casadevall
- Pierre Hirsch
- Christian Rose
- Mathieu Wemeau
- Frédéric Galacteros
- Bruno Cassinat
- Beatriz Bellosillo
- Celeste Bento
- Richard van Wijk
- Petro E. Petrides
- Maria Luigia Randi
- Mary Frances McMullin
- Peppi Koivunen
- ECYT-3 consortium
- François Girodon
- Betty Gardie
1 Application
| Application ID | Title |
|---|---|
| 49823 | Genetic predisposition to cardiovascular and metabolic diseases |
Enabling scientific discoveries that improve human health